Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Non-Current Assets (2016 - 2025)

Anaptysbio filings provide 10 years of Non-Current Assets readings, the most recent being $14.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 72.78% year-over-year to $14.1 million, compared with a TTM value of $138.9 million through Dec 2025, down 26.96%, and an annual FY2025 reading of $14.1 million, down 72.78% over the prior year.
  • Non-Current Assets hit $14.1 million in Q4 2025 for Anaptysbio, down from $22.4 million in the prior quarter.
  • The five-year high for Non-Current Assets was $168.1 million in Q3 2022, with the low at $9.3 million in Q1 2021.
  • Median Non-Current Assets over the past 5 years was $55.4 million (2024), compared with a mean of $69.3 million.
  • The sharpest move saw Non-Current Assets plummeted 82.54% in 2021, then skyrocketed 1114.17% in 2022.
  • Year by year, Non-Current Assets stood at $89.2 million in 2021, then surged by 82.95% to $163.2 million in 2022, then plummeted by 72.08% to $45.6 million in 2023, then increased by 14.06% to $52.0 million in 2024, then crashed by 72.78% to $14.1 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $14.1 million, $22.4 million, and $43.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.